Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
about
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaWhat's the place of immunotherapy in malignant mesothelioma treatments?Novel immunotherapy clinical trials in malignant pleural mesothelioma.New roads open up for implementing immunotherapy in mesothelioma.Improving lung cancer survival; time to move onDefect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.Update in lung cancer and oncological disorders 2010Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.Lung cancer: Biology and treatment options.Trial watch: Dendritic cell-based interventions for cancer therapyTumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma.Translational advances in pleural malignancies.Novel targeted therapies and vaccination strategies for mesothelioma.Medical treatment of mesothelioma: anything new?Malignant pleural mesothelioma: from the bench to the bedside.Dendritic cell-based immunotherapy in mesothelioma.Therapies currently in Phase II trials for malignant pleural mesothelioma.Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.Searching for targets for the systemic therapy of mesothelioma.Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Brain Tumor Immunotherapy: What have We Learned so Far?Switching off malignant pleural effusion formation-fantasy or future?Is immunotherapy a viable option in treating mesothelioma?Immune Therapy.Cellular immunotherapy of cancer: an overview and future directions.A catalogue of treatment and technologies for malignant pleural mesothelioma.Immunotherapy for malignant mesothelioma: Reality check.Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.Novel insights into mesothelioma biology and implications for therapy.Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.Immunological profiling as a means to invigorate personalized cancer therapy.Harnessing the Power of the Host: Improving Dendritic Cell Vaccines for Malignant Pleural Mesothelioma.Immunotherapy advances for mesothelioma treatment.Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
P2860
Q26859274-FF7DEAC7-8DF1-4CC3-AB7D-5DDE4CDB95D0Q28394028-6AB2FCB2-536E-46FA-A47D-98BD349E0ED7Q33781142-9C0D5844-F02E-48E9-9B7B-C1EB8ADBE69AQ33871577-19910211-A6CE-40CE-B547-1C504D89BF3AQ34331993-445C4683-8A88-4463-BCB4-6E0DE3D63AF2Q34509420-31884B40-7033-4F2E-89B7-27B4FCE10388Q34788477-D39EED48-CA0A-4726-9307-EC0F444A4724Q35042668-E78080C9-A08B-440B-8881-C3BB49E706DBQ35122102-4DDFFDEF-03EF-4426-81CA-7E5A4E82F574Q35219727-EBF331A3-4BF3-4901-9251-0938EA1E5DEEQ35711576-75354D36-6F9D-4452-9CCD-271D25D16F59Q35768107-D572CCC4-A24B-4E99-A763-796557044D9FQ36328370-564AFF2B-A4E4-4B71-9A0F-A3DBEF30F64DQ36388529-20090780-4924-4806-8E2C-B4ACB1495160Q37295688-14455AF0-BFDA-43DA-923F-810C951C9CBBQ37806309-2D582D56-D868-44A2-98F1-741574C1C27CQ37855667-11E604E9-1FCC-41A2-913C-039FEC6DCA52Q37866663-9E2CEEB0-574F-406E-B29E-388214AB07A4Q38019747-9E8981AB-792C-4236-8327-CA44E3724572Q38059514-DAE6D555-187C-4CDA-B092-05F1AE917B52Q38118385-8B98DCE9-7F5A-41F3-830D-344A421A47A2Q38180749-06761D41-BB6D-4FFE-8EB3-BFF9255128CCQ38365768-CA703E16-4A93-4FEF-BE37-303D2AE3C186Q38390104-F39D040D-C214-4443-9CFE-29A829540D5CQ38542113-40D54B23-57B7-4C7A-B615-8163455412ADQ38543525-2E505CB6-5B92-4BF7-9ECA-B481C9E4921EQ38647275-31D26CCB-9348-422A-A84A-11D136D236EDQ38669273-07F389DA-A48F-42D7-8EE2-3437E29B088BQ38673161-F874C2A0-F1A4-4D1B-AE89-886EC47182C1Q38760623-8E0C58E2-8EE2-49DF-9B87-1AEEAE132CE0Q39351008-EAA6FDBF-2DC1-4BD8-8621-3DF4241620C1Q39415827-FAEFF2B9-3FD5-49E3-B0FE-C5F801DD21E4Q39455555-5AFF50C0-A9C4-4D92-B7EC-1A959D74EFAAQ39467521-6E28510B-181F-4EF6-ACEA-C28A0F55D8FFQ40127604-911D1B4F-2C29-439E-8C6C-184D4B560135Q42149825-DA308E8A-BF35-4D19-B8A4-82FA7F06E031Q47862061-ADA711F5-345E-4C1A-946A-023A4DB93430Q51823843-B47C0876-5438-44C5-82D7-F85E03796E9BQ57159575-127DAFC8-FA28-4978-A22B-0E4AD18056BD
P2860
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Consolidative dendritic cell-b ...... gainst malignant mesothelioma.
@en
type
label
Consolidative dendritic cell-b ...... gainst malignant mesothelioma.
@en
prefLabel
Consolidative dendritic cell-b ...... gainst malignant mesothelioma.
@en
P2093
P2860
P1476
Consolidative dendritic cell-b ...... gainst malignant mesothelioma.
@en
P2093
Bart N Lambrecht
Henk C Hoogsteden
I Jolanda M de Vries
Joachim G Aerts
Joost P Hegmans
Joris D Veltman
Margaretha E Lambers
Rudi W Hendriks
P2860
P304
P356
10.1164/RCCM.200909-1465OC
P407
P50
P577
2010-02-18T00:00:00Z